Table 3

Demographic details and odds ratios for AD for ACE alleles and genotypes for specific case control series used for meta-analysis

Reference region		Source		Cases				Controls				Odds ratio (95% confidence interval)
Reference region		Source		No	Age (SD)			Diagnostic criteria17 18	No			Age (SD)	I v D	DI v DD	II v DD
Scacchi et al ⁸	Italy	80	83.5 (5.9)	NINCDS-ADRDA		153	78.3 (7.0)		1.05 (0.71–1.56)	1.26 (0.70–2.27)	0.96 (0.39–2.39)
Chapmanet al ⁹	Israel	49	74.8 (9.7)	NINCDS-ADRDA		40	72.7 (7.8)		1.00 (0.53–1.86)	1.32 (0.55–3.21)	0.72 (0.17–3.10)
Kehoeet al ³	Cardiff	198	70.3 (9.4)	NINCDS-ADRDA		77	73.5 (6.2)		1.56 (1.07–2.28)	2.39 (1.29–4.43)	2.56 (1.14–5.78)
Kehoeet al ³	London	135	82.3 (6.7)	NINCDS-ADRDA		111	80.8 (4.5)		1.39 (0.97–1.99)	3.13 (1.69–5.79)	1.79 (0.83–3.86)
Kehoeet al ³	Belfast	209	76.6 (6.3)	NINCDS-ADRDA		198	77.1 (6.4)		1.27 (0.96–1.67)	1.86 (1.10–3.13)	1.75 (0.99–3.11)
Palumboet al 10	Perugia	64	73 (5)	NINCDS-ADRDA		40	71 (4)		1.07 (0.60–1.90)	1.01 (0.41–2.47)	1.13 (0.39–3.22)
Alvarezet al 11	Spain	350	72 (9.0)	NINCDS-ADRDA		400	21–65 (range)		1.28 (1.04–1.58)	1.26 (0.92–1.73)	1.61 (1.06–2.44)
Huet al 12	Japan	132	73.7 (11.0)	NINCDS-ADRDA		148	75.5 (9.9)		1.59 (1.11–2.26)	1.85 (0.81–4.23)	2.70 (1.87–6.13)
Crawfordet al 13	Florida	171	72.2 (6.7)	NINCDS-ADRDA		175	73.6 (6.7)		1.23 (0.91–1.67)	1.81 (1.12–2.90)	1.27 (0.69–2.33)
Farreret al 14	Moscow	151	64.6 (8.8)	NINCDS-ADRDA		206	64.9 (11.4)		0.90 (0.67–1.22)	1.27 (0.77–2.07)	0.77 (0.42–1.42)
Farreret al 14	Toronto	236	75.2 (7.6)	NINCDS-ADRDA		169	70.2 (10.2)		0.96 (0.72–1.28)	1.17 (0.76–1.80)	0.84 (0.47–1.48)
Narainet al	England	239	81.2 (7.8)	CERAD		342	82.1 (3.8)		1.05 (0.83–1.32)	0.64 (0.43–0.95)	1.16 (0.72–1.88)